AU2804400A — Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists
Assigned to SmithKline Beecham Ltd · Expires 2000-08-29 · 26y expired
What this patent protects
The present invention provides phenyl urea and phenyl thiourea derivatives which are non-peptide antagonists of human orexin receptors, in particular orexin-1 receptors, of formula (I)in which:Z represents oxygen or sulfur; and R<1 >to R<7 >represent various substitue…
USPTO Abstract
The present invention provides phenyl urea and phenyl thiourea derivatives which are non-peptide antagonists of human orexin receptors, in particular orexin-1 receptors, of formula (I)in which:Z represents oxygen or sulfur; and R<1 >to R<7 >represent various substituent groups; and pharmaceutically acceptable salts thereof. In particular, these compounds are of potential use in the treatment of obesity including obesity observed in Type 2(non-insulin-dependent) diabetes patients and/or sleep disorders.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.